Innovotech

Innovotech EPS Growth

The EPS Growth of Innovotech (IOT.V) as of Nov 20, 2026 is -58.01 %. In the previous year, EPS Growth was 212.27 % — a change of -127.33% (lower).

EPS Growth

-58.01 %

YoY

-127.33%

Last updated:

EPS Growth of Innovotech is 2025 -58.01 % . EPS Growth of Innovotech was 2024 212.27 % . It decreases by -127.33% lower compared to the previous year.

The Innovotech EPS Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS Growth
Date
EPS Growth
Jan 1, 2018
-115.58 CAD
Jan 1, 2019
62.70 CAD
Jan 1, 2020
306.39 CAD
Jan 1, 2021
239.77 CAD
Jan 1, 2022
-137.18 CAD
Jan 1, 2023
-15.23 CAD
Jan 1, 2024
212.27 CAD
Jan 1, 2025
-58.01 CAD
The Innovotech EPS Growth history
YEAREPS GrowthYoY
-58.01 %-127.33%
212.27 %-1,493.91%
-15.23 %-88.90%
-137.18 %-157.21%
239.77 %-21.74%
306.39 %+388.67%
62.70 %-154.25%
-115.58 %-128.35%
407.63 %-936.97%
-48.70 %+149.24%
-19.54 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Innovotech Stock analysis

What does Innovotech do? Innovotech Inc. generates revenue through the sale of proprietary assay kits, including MBEC Assay Kits, Order Biofilm Assays, and Coated MBEC Assay Lids, which are used in microbial biofilm research. The company also provides contract research services such as Antimicrobial Contract Research, Antimicrobial and Anti-Biofilm Agents testing (MIC and MBEC), and Customized Antimicrobial Testing (BEST Assay Testing and Implanted Medical Device Testing). Its antimicrobial silver products, AgreGuard-1 Silver Antimicrobial for Crop Protection and InnovoSIL Antimicrobial Silver Products, are sold to customers in agricultural and medical sectors. The firm targets research institutions, agricultural producers, and medical device manufacturers seeking biofilm and antimicrobial testing solutions. Innovotech's intellectual property portfolio supports its contract research services, which include testing for antimicrobial agents and materials under standards like TM100, ISO 22196, and USP 51. The company’s Biofilm Publications and SEM Library serve as additional resources for clients engaged in biofilm research. Its product offerings are tailored to sectors requiring microbial biofilm analysis, such as crop protection and medical device development, with AgreGuard-1 and InnovoSIL products specifically addressing antimicrobial needs in agriculture and medical applications. The company monetizes its proprietary technology through direct sales of assay kits and antimicrobial silver products, while contract research services provide recurring revenue streams. Clients include research organizations conducting biofilm studies, agricultural businesses using AgreGuard-1 for crop protection, and medical device manufacturers utilizing InnovoSIL for antimicrobial properties. Innovotech’s focus on specialized testing methodologies and branded products ensures consistent demand from niche markets requiring precise biofilm and antimicrobial evaluation. Innovotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Innovotech stock

EPS Growth of Innovotech is -58.01 % in 2025.

On Eulerpool you can find the complete historical development of EPS Growth Innovotech since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's Innovotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Innovotech

All Key Metrics — Innovotech